Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022698 · ClinicalTrials.gov registry record · Phase 2
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
A Phase 2 study of Colorectal Cancer, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 17
- Study locations
NCT00022698 is a Phase 2 study of Colorectal Cancer that has completed, run by Hoffmann-La Roche. The registered enrollment target is 67 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (96% lower). The trial reports 17 study locations across 13 states.
The verdict
NCT00022698, a Phase 2 study of Colorectal Cancer, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 17
- Study locations
Study Summary
PURPOSE: Phase II trial to study the effectiveness of combining capecitabine and irinotecan in treating patients who have locally advanced, recurrent, or metastatic colorectal cancer.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Irinotecan
Study Locations (17)
District of Columbia
- Lombardi Cancer Center at Georgetown University Medical Center - Washington D.C.
- George Washington University Medical Center - Washington D.C.
New York
- HemOnCare, P.C. - Brooklyn
- Lincoln Medical and Mental Health Center - The Bronx
Pennsylvania
- Kimmel Cancer Center at Thomas Jefferson University - Philadelphia - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Washington
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus - Seattle
- Rockwood Clinic P.S. - Spokane
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
California
- Loma Linda University Cancer Institute at Loma Linda University Medical Center - Loma Linda
Connecticut
- Eastern Connecticut Hematology and Oncology Associates - Norwich
Florida
- University of Florida Health Science Center - Jacksonville - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2001-05 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022698
The ClinicalTrials.gov registry entry for NCT00022698 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Capecitabine is the first listed.
NCT00022698 reports 17 study locations spanning 13 distinct geographic areas - top geographies include District of Columbia, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00022698 about?
NCT00022698 is a clinical study titled "Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer". PURPOSE: Phase II trial to study the effectiveness of combining capecitabine and irinotecan in treating patients who have locally advanced, recurrent, or metastatic colorectal cancer.
What is the current status of trial NCT00022698?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2001-05. Estimated completion is 2004-12.
What conditions does trial NCT00022698 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT00022698?
The interventions under investigation include: Capecitabine (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00022698?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00022698 being conducted?
This trial has 17 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.